Search research articles
Contact Us
Filters
Showing results (201-210 of 236) with videos related to
Page
of 24
Sort By:
Journal of the National Cancer Institute
|
November 6, 2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Jessie Torgersen, Michael J Kallan, Dena M Carbonari, et al.
Plos One
|
July 23, 2025
Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines
Jessie Torgersen, Craig W Newcomb, Dean M Carbonari, et al.
BMJ Open
|
March 19, 2026
Postmarketing safety surveillance for GSK's AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
Sruthi Adimadhyam, Dominique Luyts, Driss Oraichi, et al.
Pharmacoepidemiology and Drug Safety
|
April 2, 2021
A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System
Noelle M Cocoros, Candace C Fuller, Sruthi Adimadhyam, et al.
Annals of the Rheumatic Diseases
|
April 3, 2021
Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial
Ho So, Isaac T Cheng, Sze-Lok Lau, et al.
JAMA Network Open
|
December 14, 2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Lamia Y Haque, David A Fiellin, Janet P Tate, et al.
Pharmacoepidemiology and Drug Safety
|
April 22, 2021
Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies
Vincent Lo Re, Dena M Carbonari, Jerry Jacob, et al.
BMJ Open Diabetes Research & Care
|
September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes
Vincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
Open Forum Infectious Diseases
|
August 19, 2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Vincent Lo Re, Michael J Kallan, Janet P Tate, et al.
Hepatology (Baltimore, Md.)
|
May 26, 2017
FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients
Kaku A So-Armah, Joseph K Lim, Vincent Lo Re, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 236) with videos related to
Sort By:
Page
of 24
Journal of the National Cancer Institute
|
November 6, 2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Jessie Torgersen, Michael J Kallan, Dena M Carbonari, et al.
Plos One
|
July 23, 2025
Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines
Jessie Torgersen, Craig W Newcomb, Dean M Carbonari, et al.
BMJ Open
|
March 19, 2026
Postmarketing safety surveillance for GSK's AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study
Sruthi Adimadhyam, Dominique Luyts, Driss Oraichi, et al.
Pharmacoepidemiology and Drug Safety
|
April 2, 2021
A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System
Noelle M Cocoros, Candace C Fuller, Sruthi Adimadhyam, et al.
Annals of the Rheumatic Diseases
|
April 3, 2021
Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial
Ho So, Isaac T Cheng, Sze-Lok Lau, et al.
JAMA Network Open
|
December 14, 2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Lamia Y Haque, David A Fiellin, Janet P Tate, et al.
Pharmacoepidemiology and Drug Safety
|
April 22, 2021
Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies
Vincent Lo Re, Dena M Carbonari, Jerry Jacob, et al.
BMJ Open Diabetes Research & Care
|
September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes
Vincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
Open Forum Infectious Diseases
|
August 19, 2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Vincent Lo Re, Michael J Kallan, Janet P Tate, et al.
Hepatology (Baltimore, Md.)
|
May 26, 2017
FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients
Kaku A So-Armah, Joseph K Lim, Vincent Lo Re, et al.
Page
of 24